• An innovative microRNA-based test (ColoFast), designed to solve a significant health priority: the high mortality rate due to colon cancer worldwide (around half of the diagnosed patients).
    • Identifying a higher number of individuals affected by preliminary stages of colon cancer (such as advanced adenomas)
    • Cutting-edge biomarkers, proving a higher reduction in colon cancer mortality than current competitors in the market.
    • Better compliance than fecal tests.
    • Addressing a clear unmet medical need in a large and expanding target population.
    • Saving lives through early detection



“This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 767419”

Comments are closed, but trackbacks and pingbacks are open.